ADC Therapeutics Announces New Employee Inducement Grant
LAUSANNE, Switzerland, Nov. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the...
Clinical Trial
PharmaForceIQ Launches Share of Answer Module to Evaluate and Act on AI Visibility
Connects AI visibility audits with prioritized actions to help biopharma teams improve how brands and disease education content are represented...
Navigating the Evolving Landscape of Glomerular Disease Clinical Trials, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn how cross-functional clinical expertise can support the design and execution of glomerular disease clinical trials....
Marijuana Rescheduling In Peril: AMA Demands FDA Scientific Standards As GAO Report Exposes Malaise
MMJ International Holdings CEO Duane Boise Says "The American Medical Association October 28 Letter and Congressional Watchdog's GAO Findings Raise...
Dr. Carlos Sanchez Speaks on Structural Heart Disease at TCT 2026
Interventional cardiologist contributes to four TCT 2026 sessions in San Diego as a speaker, panelist, and discussant, sharing his heart...
Vicapsys Life Sciences Provides Shareholder Update on VICAPSYN(TM) Program Advancing Toward Phase 1 Human Clinical Trial, Vertically Integrated With the Company’s Indian Health Service Strategy
VICAPSYN™, the Company's immune-isolation technology for islet cell transplantation in type 1 diabetes, remains an active asset of Vicapsys and...
Rhelion Life Sciences’ Wholly Owned Subsidiary Filament Health Completes New Extraction of IBEX011, Its Naturally Derived Ibogaine Drug Candidate, and Commences Stability Testing
Filament has completed a new extraction of IBEX011The Company expects Filament to begin stability testing on the new extract shortlyToronto,...
Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation
Björn Tackenberg, M.D. Ph.D. FEAN FAAN, Professor of Neurology, will lead Oculis’ global integrated scientific strategy supporting the advancement of...
Nouscom Strengthens Leadership and Operational Capabilities, Appointing Loredana Siani, Ph.D., as Chief Technology Officer
Nouscom Strengthens Leadership and Operational Capabilities, Appointing Loredana Siani, Ph.D., as Chief Technology Officer Promotion follows recent €120 million Series...
Glioblastoma Foundation’s Genomic Testing & Research Laboratory Now Accepting Patient Samples for Genomic Testing
The Foundation's CLIA-certified laboratory combines DNA methylation profiling, MGMT status, copy-number variation analysis and glioblastoma subtype characterization in a single...
Life Extension and PIPA Search 600,000 Molecules in 13 Weeks and Identify New Bioactive Candidates
Powered by PIPA's Food Innovation Operating System (FIOS®), this landmark collaboration demonstrates a new model for ingredient discovery. A brand...
Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results
NIAID-RNCP elects to evaluate the efficacy of Entolimod on gastrointestinal acute radiation syndrome ("GI-ARS"), after the announcement of positive safety...
Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution
This international award, honoring “the best of the best” in medical innovation, represents yet another important external recognition of AI-Immunology™...
Nicox Reports First Half 2026 Financial Results
Press Release Nicox Reports First Half 2026 Financial Results Revenue increased to €3.5 million compared to €1.5 million in H1...
Leads Biolabs Doses First Patient with Systemic Lupus Erythematosus in Phase I Part B Trial of LBL-047, a First-in-Class BDCA2/TACI Bifunctional Fusion Protein
Dual-Target Approach Designed to Modulate Both Innate and Adaptive Immunity Advances Into Clinical Evaluation in Patients With SLENANJING, China, Oct....
Supernus Announces Third Quarter 2026 Financial Results
Record total revenues of $226.8 million in the third quarter 2026, an 18% increase compared to same period last year.Combined...
Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates
 - Phase 2 pancreatic cancer follow-up extended as patients on atebimetinib combinations live longer than projected - - Updated Phase...
Merit Medical Reports Third Quarter 2026 Results: Delivers 9% Organic Constant Currency Revenue Growth and Raises Full-Year 2026 Guidance
Financial Highlights†Reported revenue of $416.2 million, up 8.4%Constant currency revenue* and constant currency revenue, organic* up 8% and up...
Merit Medical Acquires Solo Pace, Inc., Expanding Its Cardiac Therapies Platform with Innovative TAVR Pacing Technology
Solo Pace, Inc. specializes in temporary pacing solutions and systems designed for transcatheter heart valve procedures, including transcatheter aortic valve...
BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates
- $353.2 million in total third quarter revenues, primarily comprised of $253.2 million of U.S. Attruby net product revenue (up...